Archive
All News
Every briefing, headline, and filing we've published, newest first.
MoneyFierceBiotech ↗
The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing fro…
PolicyFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
PipelineFierceBiotech ↗
Many gene therapy outfits focus on technical advances, Ocugen CEO Shankar Musunuri, Ph.D., said, meaning they …
PipelineFiercePharma ↗
Rather than relying on patient groups to make an impassioned plea, Roche aims to put doubts to rest around the…
PipelineFiercePharma ↗
Travere is eyeing a collective $3 billion U.S. opportunity for Filspari thanks to a new rare kidney disease no…
MoneyFiercePharma ↗
Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest…
PipelineFierceBiotech ↗
After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning t…
PolicyFiercePharma ↗
The legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on…
DealsBriefing
UCB’s $650M-plus purchase of Neurona Therapeutics signals a move beyond small molecules into regenerative neur…
Money
Backed by Pfizer Ventures and M Ventures, Storm Therapeutics’ $56M Series C funds a Phase 2 sarcoma trial and …
Policy
Gilead plans to supply Yeztugo to 3M people through 2028 via Global Fund partnerships, but MSF calls the scale…
DealsBriefing
Novo Nordisk unveiled a global AI collaboration with OpenAI, extending from drug discovery to manufacturing as…
Deals
Aligos sells Greater China rights to its phase 2 HBV drug for $25M upfront and up to $420M in milestones, as A…
Pipeline
A 17-trial review of 20,342 subjects found “absent or trivial” benefit from anti-amyloid drugs like Leqembi an…
MoneyBriefing
The Waltham-based obesity biotech priced at the top of its range, surpassing Moderna’s 2018 record and signali…
Pipeline
Lilly’s oral GLP-1 Foundayo showed non-inferiority to insulin glargine in Type 2 diabetes, addressing FDA safe…
Policy
Reclassification of 12 unapproved peptides ahead of a July advisory meeting marks a sharp policy turn, raising…
PipelineSTAT News ↗
"I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.…
The WeekEndpoints News ↗
The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed…
PolicySTAT News ↗
New research questions GLP-1's purpose, a pancreatic cancer breakthrough, and more biotech news from The Reado…
DealsEndpoints News ↗
Biovac’s new vaccine factory in Cape Town, which is expected to make up to 400 million vaccines per year, has …
The WeekSTAT News ↗
New research challenges what we know about GLP-1s, vaccine skepticism, and more health news from Morning Round…
MoneyPharmaVoice ↗
Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pa…
PipelinePharmaVoice ↗
Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a po…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.